Volume : 09, Issue : 12, December – 2022
Title:
86.METHOD DEVELOPMENT AND VALIDATION FOR DEFERIPRONE BY RP-HPLC METHOD
Authors :
A.Mounika, V.Kiran Kumar
Abstract :
Another investigative technique was set up for estimation of RP-HPLC strategy utilizing deferiprone cases. The chromatographic conditions were effectively created for the partition of Deferiprone by utilizing INERTSIL column, C18(150×4.6 ID) 5µm, stream rate 1.0ml/min, versatile stage proportion Triethylamine Buffer: ACN (50:50v/v), recognition frequency was 280nm. The maintenance time was seen as 4.9mins. The % virtue of deferiprone was seen as 99.08%. The framework appropriateness boundaries for deferiprone, for example, hypothetical plates and following elements were seen as 2567,1.512. The logical technique was approved according to ICH guidelines (ICH, Q2, (R1)). The linearity concentrate for Deferiprone was found in fixation scope of 125-375µg/ml and relationship coefficient were seen as 0.994. The % recuperation was seen as 98.40%. The %RSD was seen as 0.28. The accuracy study was precise, robust and repeatable. LOD esteem was 22.93µg/ml and LOQ esteem was 96.37µg/ml. As this strategy has shorter maintenance time and high goal, makes the technique more satisfactory and financially savvy and can be viably applied for routine examination in research establishments, quality control divisions in ventures and in clinical pharmacokinetic concentrates in not-so-distant future.
Keywords: Deferiprone, RP‐HPLC, Method development, Validation
Cite This Article:
Please cite this article in press A.Mounika et al, Method Development And Validation For Deferiprone By RP-HPLC Method.., Indo Am. J. P. Sci, 2022; 09(12).
Number of Downloads : 10
References:
:
1. Roberts DJ, Brunskill SJ, Doree C, Williams S, Howard J, Hyde CJ: Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD004839. [Article]
2. Victor Hoffbrand A: Deferiprone therapy for transfusional iron overload. Best Pract Res Clin Haematol. 2005 Jun;18(2):299-317. [Article]
3. FDA Approved Drug Products: Ferriprox (deferiprone) oral tablets [Link]
4. Hinesha Barot, Darshil Shah, Dr. DilipMaheshwari. Development of stability indicating UV Spectroscopy method development for the estimation of deferiprone in pharmaceutical formulation. Am. J. PharmTech Res, 5(1), 2015, 622-632.
5. Manzoor Ahmed, Vinod Kumar Jangade, Satishkumar Shetty A, Vijaya Krishna C. Aradhya, Anil Kumar S.M. Development and validation of first order derivative spectrophotometric method for the estimation of deferiprone in bulk and capsule dosage form.Int.J.of universal pharmacy and biosciences. 4(3), 2015, 169-176.
6. Manzoor Ahmed, Vinod Kumar Jangade*, Satishkumar Shetty A, Vijayakrishna C. Aradhya, Kuppast I.J and Anil kumar S.M. RP-HPLC method development and validation for estimation of deferiprone in capsule dosage form. World Journal of Pharmacy and Pharmaceutical Sciences. 4(3), 2015, 831-838.
7. Mateen Abbas, Rakhshanda Nawaz, Tahira Iqbal2, Muhammad Alim, Muhammad Rafique Asi. Quantitative determination of deferiprone in human plasma by reverse phase high performance liquid chromatography and its application to pharmacokinetic study. Pak. J. Pharm. Sci.25(2), 2012, 343-348.